fenoldopam has been researched along with Cardiac Failure in 23 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 9.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 7.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "Fenoldopam (SKF 82526 J) is a selective DA-1 receptor agonist and thus of a potential benefit for promoting afterload reduction, renal vasodilatation, and diuresis in congestive heart failure." | 7.67 | Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure. ( Jover, BF; McGrath, BP, 1988) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 7.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| "Fenoldopam (SKF-82526-J) is a new, orally available, selective, dopamine-receptor agonist with potent renal vasodilating properties (six times that of dopamine) without positive inotropic or adrenergic activity." | 6.66 | Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. ( Aronoff, RD; Leon, CA; Pratt, CM; Roberts, R; Suarez, JM; Young, JB, 1985) |
| " In 15 patients with a mean radionuclide ejection fraction of 17%, the agents were infused in a random-ordered, double-blinded, crossover, active drug-controlled protocol after optimal dosing was determined during a titration period." | 6.66 | Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside. ( Kingry, C; Leon, CA; Pratt, CM; Roberts, R; Taylor, AA; Young, JB, 1988) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 6.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 5.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients." | 5.06 | A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. ( Jeffrey, RF; Lee, MR; MacDonald, TM; Muir, AL, 1990) |
| " The novel DA1 receptor agonist fenoldopam is claiming a role in the management of hypertension, heart failure, and the preservation of renal function." | 4.78 | Dopamine and dopamine receptor agonists in cardiovascular therapy. ( Elliott, WJ; Murphy, MB, 1990) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 3.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "Fenoldopam (SKF 82526 J) is a selective DA-1 receptor agonist and thus of a potential benefit for promoting afterload reduction, renal vasodilatation, and diuresis in congestive heart failure." | 3.67 | Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure. ( Jover, BF; McGrath, BP, 1988) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 3.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| "Fenoldopam (SKF-82526-J) is a new, orally available, selective, dopamine-receptor agonist with potent renal vasodilating properties (six times that of dopamine) without positive inotropic or adrenergic activity." | 2.66 | Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure. ( Aronoff, RD; Leon, CA; Pratt, CM; Roberts, R; Suarez, JM; Young, JB, 1985) |
| " In 15 patients with a mean radionuclide ejection fraction of 17%, the agents were infused in a random-ordered, double-blinded, crossover, active drug-controlled protocol after optimal dosing was determined during a titration period." | 2.66 | Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside. ( Kingry, C; Leon, CA; Pratt, CM; Roberts, R; Taylor, AA; Young, JB, 1988) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 2.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (43.48) | 18.7374 |
| 1990's | 8 (34.78) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nussmeier, NA | 1 |
| Cohen, MG | 1 |
| Allie, DE | 1 |
| Hebert, CJ | 1 |
| Walker, CM | 1 |
| Pucelikova, T | 1 |
| Dangas, G | 1 |
| Mehran, R | 1 |
| Patel, JJ | 1 |
| Mitha, AS | 1 |
| Sareli, P | 1 |
| de Vaal, JB | 1 |
| Smit, AJ | 2 |
| Blanchett, DG | 1 |
| Green, JA | 3 |
| Nara, A | 1 |
| Pospisil, R | 2 |
| Jarvis, RC | 3 |
| Kasmer, RJ | 3 |
| Boyle, DA | 1 |
| Cyronak, MJ | 1 |
| Corder, CN | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Murphy, MB | 1 |
| Elliott, WJ | 1 |
| Munger, MA | 1 |
| Benotti, JR | 1 |
| Nara, AR | 2 |
| McCue, JE | 1 |
| Pospisil, RA | 1 |
| MacDonald, TM | 1 |
| Jeffrey, RF | 1 |
| Muir, AL | 1 |
| Lee, MR | 1 |
| Holcslaw, TL | 1 |
| Beck, TR | 1 |
| Casagrande, C | 1 |
| Merlo, L | 1 |
| La Regina, A | 1 |
| Jover, BF | 1 |
| McGrath, BP | 1 |
| Hassan, E | 1 |
| Carey, RA | 1 |
| Jacob, L | 1 |
| Hasenfuss, G | 1 |
| Just, H | 1 |
| Strocchi, E | 1 |
| Tartagni, F | 1 |
| Malini, PL | 1 |
| Valtancoli, G | 1 |
| Ambrosioni, E | 1 |
| Pasinelli, F | 1 |
| Riva, E | 1 |
| Fuccella, LM | 1 |
| Goldberg, LI | 1 |
| Rajfer, SI | 1 |
| Young, JB | 2 |
| Leon, CA | 2 |
| Pratt, CM | 2 |
| Suarez, JM | 1 |
| Aronoff, RD | 1 |
| Roberts, R | 2 |
| Shebuski, RJ | 1 |
| Smith, JM | 1 |
| Ruffolo, RR | 1 |
| Kingry, C | 1 |
| Taylor, AA | 1 |
| Francis, GS | 1 |
| Wilson, BC | 1 |
| Rector, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pre-existing Microalbuminuria Predicting Contrast-induced Acute Kidney Injury (CIAKI) Following Coronary Angiography (CAG)[NCT02808845] | 800 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| Early Detection of Contrast Induced Nephropathy After Coronary Angiography : Predictive Value of Osteopontin[NCT05547581] | 155 participants (Anticipated) | Observational | 2022-12-07 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for fenoldopam and Cardiac Failure
| Article | Year |
|---|---|
Improving perioperative outcomes in patients with end-stage heart failure.
Topics: Cardiac Surgical Procedures; Dopamine Agonists; Fenoldopam; Heart Failure; Heart Transplantation; He | 2003 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Contrast-induced nephropathy.
Topics: Acetylcysteine; Acute Kidney Injury; Calcium Channel Blockers; Contrast Media; Coronary Angiography; | 2008 |
Dopamine in heart failure and critical care.
Topics: Cardiotonic Agents; Controlled Clinical Trials as Topic; Critical Care; Deoxyepinephrine; Dopamine; | 2000 |
Dopamine and dopamine receptor agonists in cardiovascular therapy.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Biological Availability; Blood Pressure; | 1990 |
Clinical experience with intravenous fenoldopam.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Cardiovascular System; Chemical Phenomen | 1990 |
Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Deoxyepinephrine; Dopamine; Dop | 1990 |
The role of dopaminergic agents and the dopamine receptor in treatment for CHF.
Topics: Benzazepines; Deoxyepinephrine; Dobutamine; Dopamine; Dopamine Agents; Fenoldopam; Heart Failure; Hu | 1989 |
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D | 1989 |
5 trials available for fenoldopam and Cardiac Failure
| Article | Year |
|---|---|
Intravenous fenoldopam infusion in severe heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Diuretics; Dopamine Agents; Dose- | 1993 |
The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Adult; Aged; Biolo | 1991 |
A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Body Weight; Coronary Disease; Dop | 1990 |
Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure.
Topics: Benzazepines; Fenoldopam; Heart Failure; Hemodynamics; Humans; Vascular Resistance | 1985 |
Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside.
Topics: Adult; Benzazepines; Double-Blind Method; Female; Fenoldopam; Ferricyanides; Heart Failure; Hemodyna | 1988 |
10 other studies available for fenoldopam and Cardiac Failure
| Article | Year |
|---|---|
First experience with intra-renal fenoldopam in a patient with heart failure.
Topics: Aged; Cardiac Catheterization; Catheterization; Electrocardiography; Equipment Design; Equipment Saf | 2005 |
Multifactorial acute renal failure treated with percutaneous targeted renal therapy (TRT): a case of "dialysis rescue".
Topics: Acute Kidney Injury; Administration, Cutaneous; Aged; Catheterization; Diabetic Nephropathies; Fenol | 2007 |
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Aged, 80 and over; Drug Tol | 1990 |
Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure.
Topics: Animals; Benzazepines; Cardiac Output; Catecholamines; Cerebrovascular Circulation; Disease Models, | 1988 |
Continuous monitoring of mixed venous oxygen saturation as an indicator of pharmacologic intervention.
Topics: Benzazepines; Cardiac Catheterization; Cardiac Output; Fenoldopam; Heart Failure; Humans; Male; Midd | 1989 |
Interaction study of fenoldopam--digoxin in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Digoxin; Dopamine Agents; D | 1989 |
Dopamine receptors: applications in clinical cardiology.
Topics: Administration, Oral; Arrhythmias, Cardiac; Benzazepines; Bromocriptine; Deoxyepinephrine; Fenoldopa | 1985 |
Comparison of the renal and pulmonary hemodynamic effects of fenoldopam, dobutamine, dopamine and norepinephrine in the anesthetized dog.
Topics: Animals; Benzazepines; Cardiotonic Agents; Dobutamine; Dogs; Dopamine; Female; Fenoldopam; Heart Fai | 1988 |
Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.
Topics: Administration, Oral; Aldosterone; Arginine Vasopressin; Benzazepines; Fenoldopam; Heart Failure; He | 1988 |